Valbenazine tosylate is a Small Molecule owned by Neurocrine Biosciences, and is involved in 45 clinical trials, of which 38 were completed, 3 are ongoing, and 4 are planned.

NBI-98854 acts as an vesicular monoamine transporter2 inhibitor (VMAT2). It is responsible for the translocation of monoamines (serotonin, dopamine, norepinephrine, and histamine) from the cytoplasm into synaptic vesicles via a proton electrochemical gradient generated by the vacuolar type H+-adenosine triphosphatase. VMAT2 is effective in regulating the levels of dopamine release during nerve communication. Vesicular monoamine transporter 2 (VMAT2) is the only transporter that moves cytoplasmic dopamine (DA) into synaptic vesicles for storage and subsequent exocytotic release. By inhibiting its function the disease progression is checked.

The revenue for Valbenazine tosylate is expected to reach a total of $24.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Valbenazine tosylate NPV Report.

Valbenazine tosylate is originated and owned by Neurocrine Biosciences.

Valbenazine tosylate Overview

Valbenazine tosylate (NBI-98854, Ingrezza) is an anti-dyskinesia agent. It is formulated as hard gelatin capsules for oral route of administration. Valbenazine is indicated for the treatment of central nervous system disorders including tardive dyskinesia in schizophrenia patients, adjunctive treatment in schizophrenia and for dyskinesia due to cerebral palsy. It acts by targeting vesicular monoamine transporter type 2.

Valbenazine tosylate is also under development for the treatment of chorea associated with Huntington's disease, trichotillomania and tardive dyskinesia.

The drug candidate was also under development for the treatment of tourette syndrome (in adults and pediatrics).

Neurocrine Biosciences Overview

Neurocrine Biosciences (Neurocrine) discovers, develops, and sells pharmaceutical products for the treatment of neurologic, psychiatric, and endocrine-related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule, is a US FDA-approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). The company’s other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids, and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson’s disease. The company also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. Neurocrine is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$1,133.5 million for the fiscal year ended December 2021 (FY2021), an increase of 8.4% over FY2020. In FY2021, the company’s operating margin was 9%, compared to an operating margin of 13.8% in FY2020. In FY2021, the company recorded a net margin of 7.9%, compared to a net margin of 38.9% in FY2020. The company reported revenues of US$387.9 million for the third quarter ended September 2022, an increase of 2.6% over the previous quarter.

Quick View – Valbenazine tosylate

Report Segments
  • Innovator (NME)
Drug Name
  • Valbenazine tosylate
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.